EP3426676A1 - Polypeptide gb de cytomégalovirus humain - Google Patents

Polypeptide gb de cytomégalovirus humain

Info

Publication number
EP3426676A1
EP3426676A1 EP17713783.3A EP17713783A EP3426676A1 EP 3426676 A1 EP3426676 A1 EP 3426676A1 EP 17713783 A EP17713783 A EP 17713783A EP 3426676 A1 EP3426676 A1 EP 3426676A1
Authority
EP
European Patent Office
Prior art keywords
polypeptide
seq
amino acid
acid sequence
cmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17713783.3A
Other languages
German (de)
English (en)
Inventor
Xiaoyuan Sherry CHI
Xinzhen Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of EP3426676A1 publication Critical patent/EP3426676A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect

Abstract

La présente invention concerne un polypeptide qui comprend au moins une mutation au niveau de la région de boucle de fusion 1 et/ou au niveau de la région de boucle de fusion 2 et/ou au niveau du site de clivage de type furine d'un polypeptide gB de cytomégalovirus humain. Dans un mode de réalisation, le polypeptide subit un changement de conformation structurale en réponse à un changement de pH.
EP17713783.3A 2016-03-11 2017-03-09 Polypeptide gb de cytomégalovirus humain Withdrawn EP3426676A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307423P 2016-03-11 2016-03-11
PCT/IB2017/051401 WO2017153954A1 (fr) 2016-03-11 2017-03-09 Polypeptide gb de cytomégalovirus humain

Publications (1)

Publication Number Publication Date
EP3426676A1 true EP3426676A1 (fr) 2019-01-16

Family

ID=58413151

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17713783.3A Withdrawn EP3426676A1 (fr) 2016-03-11 2017-03-09 Polypeptide gb de cytomégalovirus humain

Country Status (3)

Country Link
EP (1) EP3426676A1 (fr)
CA (1) CA3016867A1 (fr)
WO (1) WO2017153954A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220023416A1 (en) * 2018-12-10 2022-01-27 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
AU2021287508B2 (en) * 2020-06-09 2023-11-09 Km Biologics Co., Ltd. Fusion protein of pentamer and gB of cytomegalovirus, and vaccine containing said fusion protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (fr) 1989-05-25 1990-12-13 Chiron Corporation Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
SG10201608381SA (en) 2008-07-16 2016-11-29 Inst Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US20130216613A1 (en) * 2010-10-15 2013-08-22 Guy Jean Marie Fernand Pierre Baudoux Cytomegalovirus gb antigen
EP3031822A1 (fr) * 2014-12-08 2016-06-15 Novartis AG Antigènes du cytomégalovirus

Also Published As

Publication number Publication date
WO2017153954A1 (fr) 2017-09-14
CA3016867A1 (fr) 2017-09-14

Similar Documents

Publication Publication Date Title
US20230109393A1 (en) Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19)
US8715695B2 (en) Polypeptide fragments of the hepatitis E virus, the vaccine composition comprising said fragments and the diagnostic kits
Block et al. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice
US20150086578A1 (en) Human cytomegalovirus vaccine
US11629172B2 (en) Human cytomegalovirus gB polypeptide
Fowler et al. Marker vaccine potential of a foot-and-mouth disease virus with a partial VP1 GH loop deletion
CN107531761A (zh) 巨细胞病毒抗原及其用途
TWI445547B (zh) 登革熱病毒胜肽疫苗及其製備與使用方法
US11857622B2 (en) Human cytomegalovirus GB polypeptide
US20140050754A1 (en) Immunogenic chikungunya virus peptides
JP4750024B2 (ja) Ｓａｒｓの免疫原を発現するベクター、そのようなベクター又はその発現産物を含有する組成物、並びにその作製及び使用の方法及びアッセイ
CN108210921A (zh) 一种寨卡病毒疫苗及其制备方法
KR20220009959A (ko) Csfv 서브유닛 백신
US10611800B2 (en) Human cytomegalovirus gB polypeptide
WO2017153954A1 (fr) Polypeptide gb de cytomégalovirus humain
KR20190096965A (ko) 선천적 진전 a를 야기하는 신규한 페스티바이러스의 단리
KR101966841B1 (ko) 지카바이러스 e 단백질 유래의 재조합 항원 및 이의 용도
CA2526640A1 (fr) Reactifs immunogenes provenant du virus du nil occidental
US20080075738A1 (en) Chimeric T helper-B cell peptide vaccine for Japanese encephalitis virus
CN115894713B (zh) 异源三聚体化融合蛋白、组合物及其应用
WO1995004147A1 (fr) Produits de synthese recombinants utilisant des sequences de remplacement dans les regions hypervariables

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181011

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200128

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211001